Cited by 190Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsDementia and Cognitive Impairment Research

Anti-Aβ antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice

Open access
Brendza, Robert P., Bacskai, Brian J., Cirrito, John R., Simmons, Kelly A., Skoch, Jesse M., Klunk, William E., Mathis, Chester A., Bales, Kelly R. +3 more·2005·Journal of Clinical Investigation

Abstract

Neuritic plaques are a defining feature of Alzheimer disease (AD) pathology. These structures are composed of extracellular accumulations of amyloid-beta peptide (Abeta) and other plaque-associated proteins, surrounded by large, swollen axons and dendrites (dystrophic neurites) and activated glia. Dystrophic neurites are thought to disrupt neuronal function, but whether this damage is static, dynamic, or reversible is unknown. To address this, we monitored neuritic plaques in the brains of living PDAPP;Thy-1:YFP transgenic mice, a model that develops AD-like pathology and also stably expresses yellow fluorescent protein (YFP) in a subset of neurons in the brain. Using multiphoton microscopy, we observed and monitored amyloid through cranial windows in PDAPP;Thy-1:YFP double-transgenic mice using the in vivo amyloid-imaging fluorophore methoxy-X04, and individual YFP-labeled dystrophic neurites by their inherent fluorescence. In vivo studies using this system suggest that amyloid-associated dystrophic neurites are relatively stable structures in PDAPP;Thy-1:YFP transgenic mice over several days. However, a significant reduction in the number and size of dystrophic neurites was seen 3 days after Abeta deposits were cleared by anti-Abeta antibody treatment. This analysis suggests that ongoing axonal and dendritic damage is secondary to Abeta and is, in part, rapidly reversible.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci23269

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Knowles, R.B., et al. 1999. Plaque-induced neurite abnormalities: implications for disruption of neu- ral networks in Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 96:5274-5279.

Cited by

Sorted by citations

Authors
Brendza, R. P., Bacskai, B. J., Cirrito, J. R., Simmons, K. A., Skoch, J. M., Klunk, W. E., Mathis, C. A., Bales, K. R., Paul, S. M., Hyman, B. T., & Holtzman, D. M.
Affiliations
  • Washington University in St. Louis (US)
  • Harvard University (US)
  • University of Pittsburgh (US)
  • Eli Lilly (United States) (US)
Corresponding author
Holtzman, David M.
Venue
Journal of Clinical Investigation
Published
2005-01-20
Volume
115
Issue
2
Pages
428-433
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2126885422
Cited by
190
References
6
Citations by year
2026: 3 · 2025: 3 · 2024: 5 · 2023: 4 · 2022: 2 · 2021: 4 · 2020: 4 · 2019: 2 · 2017: 5 · 2016: 5 · 2015: 5 · 2014: 2 · 2013: 10 · 2012: 7
FWCI
15.69
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
Funders
  • Alzheimer's Association (EB00768, AG13956)
  • American Health Assistance Foundation
  • Eli Lilly and Company
  • National Institutes of Health (AG13956, AG08487)
  • National Institute on Aging (AG20222, AG-08487, R01AG020222, R01AG013956, R01AG008487, R01AG020570, R37AG013956, AG13956, AG 020570)
  • National Institute of Neurological Disorders and Stroke (P01NS032636)
  • National Institute of Biomedical Imaging and Bioengineering (EB-00768, R01EB000768)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
amyloid-beta, neuritic plaques, dystrophic neurites, Alzheimer's disease
MeSH terms
Alzheimer Disease, Animals, Antibodies, Monoclonal, Mice, Transgenic, Radiography, Neurites, Amyloid beta-Protein Precursor, Neuroaxonal Dystrophies, Tomography, Optical, Mice, Plaque, Amyloid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review